Published in Int Immunol on April 01, 1996
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med (1998) 3.56
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
Protective immunity to nematode infection is induced by CTLA-4 blockade. J Exp Med (1997) 1.72
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A (2000) 1.31
A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol (2012) 1.24
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. J Exp Med (1999) 1.18
CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest (2004) 1.14
CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. Blood (2009) 1.04
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol (2006) 0.97
Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med (2015) 0.95
Regulation of the small GTPase Rap1 and extracellular signal-regulated kinases by the costimulatory molecule CTLA-4. Mol Cell Biol (2005) 0.95
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol Immunother (2013) 0.90
Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA4 antibody. Infect Immun (1999) 0.89
Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer (Auckl) (2015) 0.86
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol (2013) 0.85
CTLA-4 blockade inhibits induction of Helicobacter pylori-associated gastritis in mice. Clin Exp Immunol (2004) 0.82
CD28 co-stimulation in T-cell homeostasis: a recent perspective. Immunotargets Ther (2015) 0.78
Identification, by systematic RNA sequencing, of novel candidate biomarkers and therapeutic targets in human soft tissue tumors. Lab Invest (2015) 0.77
CD28 ligation increases macrophage suppression of T-cell proliferation. Cell Mol Immunol (2012) 0.76
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther (2016) 0.75
Differentiation-dependent differences in murine T cell susceptibility to negative regulation by the lung. Am J Respir Cell Mol Biol (2011) 0.75
Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future Oncol (2016) 0.75
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 7.15
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol (1982) 5.92
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 5.32
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17
Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell (1988) 3.88
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature (1988) 3.48
Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol (1992) 3.37
Orbital venous anomalies. Ophthalmology (1997) 3.25
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A (1998) 2.78
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity (1997) 2.72
Costimulatory regulation of T cell function. Curr Opin Cell Biol (1999) 2.69
Nontraumatic subperiosteal orbital hemorrhage. Ophthalmology (2001) 2.55
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. J Exp Med (1987) 2.52
Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science (1991) 2.49
Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature (1987) 2.38
Biphasic and protracted anaphylaxis. J Allergy Clin Immunol (1986) 2.36
Co-stimulation in T cell responses. Curr Opin Immunol (1997) 2.35
Illness behavior and the sick role in chronic disease. The case of multiple sclerosis. Soc Sci Med (1982) 2.25
Precision and accuracy of commercial laboratories' ability to classify positive and/or negative allergen-specific IgE results. Ann Allergy Asthma Immunol (2001) 2.23
The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev (1996) 2.18
Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol (1987) 2.17
Biomechanics of baseball pitching. A preliminary report. Am J Sports Med (1985) 2.08
Modulation of cyclic AMP in purified rat mast cells. I. Responses to pharmacologic, metabolic, and physical stimuli. J Immunol (1975) 2.07
Potentiation of mast cell mediator release by adenosine. J Immunol (1978) 2.05
The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell (1983) 2.04
Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells. Nature (1987) 2.00
Disability resulting from occupational low back pain. Part I: What do we know about primary prevention? A review of the scientific evidence on prevention before disability begins. Spine (Phila Pa 1976) (1996) 1.97
CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med (1993) 1.93
Determinants of duration of disability and return-to-work after work-related injury and illness: challenges for future research. Am J Ind Med (2001) 1.79
Identification of antigen receptor-associated structures on murine T cells. Nature (1985) 1.79
Disability resulting from occupational low back pain. Part II: What do we know about secondary prevention? A review of the scientific evidence on prevention after disability begins. Spine (Phila Pa 1976) (1996) 1.76
The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol (1990) 1.74
Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. Nature (1990) 1.73
Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature (1989) 1.73
Transfection of the malaria parasite and expression of firefly luciferase. Proc Natl Acad Sci U S A (1993) 1.70
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A (1999) 1.70
Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci U S A (1997) 1.67
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 1.61
The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol (2001) 1.57
Activation of phospholipid metabolism during mediator release from stimulated rat mast cells. J Immunol (1979) 1.54
Modulation of cyclic AMP in purified rat mast cells. II. Studies on the relationship between intracellular cyclic AMP concentrations and histamine release. J Immunol (1975) 1.52
Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody. Proc Natl Acad Sci U S A (1989) 1.49
Branch retinal artery occlusion in a child. Aust N Z J Ophthalmol (1996) 1.49
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48
Desensitization of patients allergic to penicillin using orally administered beta-lactam antibiotics. J Allergy Clin Immunol (1982) 1.48
Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol (1998) 1.45
Analytic precision and accuracy of commercial immunoassays for specific IgE: establishing a standard. J Allergy Clin Immunol (2000) 1.44
Mutualistic asexual endophytes in a native grass are usually parasitic. Am Nat (2003) 1.44
Delta is the Cx-gene product in the gamma/delta antigen receptor of dendritic epidermal cells. Nature (1988) 1.41
Floppy eyelid syndrome and mental retardation. Ophthalmology (2000) 1.39
Two signals are required for negative selection of CD4+CD8+ thymocytes. J Immunol (1993) 1.39
Skin testing to detect penicillin allergy. J Allergy Clin Immunol (1981) 1.37
Cardiac disorders in penicillin-induced anaphylaxis. Association with intravenous epinephrine therapy. JAMA (1982) 1.37
Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci U S A (1997) 1.36
Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med (1985) 1.36
Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. J Immunol (1986) 1.33
Monoclonal antibodies recognizing oval cells induced in the liver of rats by N-2-fluorenylacetamide or ethionine in a choline-deficient diet. Cancer Res (1985) 1.32
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A (2000) 1.31
Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol (1978) 1.31
Squamous cell carcinoma of the eyelids. Br J Ophthalmol (2002) 1.29
Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A (1993) 1.29
Primary localised amyloidosis of the orbit. Br J Ophthalmol (1996) 1.28
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol (1991) 1.28
Modulation of cyclic AMP in purified rat mast cells. III. Studies on the effects of concanavalin A and anti-IgE on cyclic AMP concentrations during histamine release. J Immunol (1976) 1.26
Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med (1996) 1.25
Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol (1997) 1.24
Possible role of arachidonic acid and its metabolites in mediator release from rat mast cells. J Immunol (1979) 1.23
CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol (1994) 1.18
A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. Cell (1987) 1.15
Concanavalin A-induced histamine release from normal rat mast cells. J Immunol (1975) 1.15
The intertrochanteric hip fracture. A retrospective analysis. Orthopedics (1988) 1.14
Survival after rhino-orbital-cerebral mucormycosis in an immunocompetent patient. Ophthalmology (2000) 1.13
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci U S A (2000) 1.13
Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies. J Immunol (1986) 1.12
Monoclonal antibodies to immunoglobulin G4 induce histamine release from human basophils in vitro. J Allergy Clin Immunol (1982) 1.12
Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer (2009) 1.12
Pathogenesis and management of allergic reactions to penicillin and other beta-lactam antibiotics. Pediatr Infect Dis (1983) 1.10
Diacylglycerol metabolism in mast cells: a potential role in membrane fusion and arachidonic acid release. J Exp Med (1979) 1.10
Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. Exp Cell Res (1985) 1.09
Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res (1994) 1.08